Millennium Management LLC Raises Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Millennium Management LLC grew its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 91.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,653,241 shares of the company's stock after buying an additional 790,437 shares during the period. Millennium Management LLC owned 0.62% of Autolus Therapeutics worth $3,885,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jane Street Group LLC acquired a new position in Autolus Therapeutics during the fourth quarter worth $26,000. Barclays PLC boosted its position in shares of Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after acquiring an additional 10,866 shares during the last quarter. Dumont & Blake Investment Advisors LLC purchased a new stake in shares of Autolus Therapeutics in the fourth quarter valued at about $35,000. Daiwa Securities Group Inc. increased its position in Autolus Therapeutics by 55.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its stake in Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after purchasing an additional 6,081 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

Shares of AUTL stock traded up $0.16 during trading hours on Tuesday, hitting $2.07. The company had a trading volume of 5,900,970 shares, compared to its average volume of 1,527,588. The stock has a market capitalization of $550.91 million, a PE ratio of -1.71 and a beta of 1.77. The company's fifty day moving average is $1.43 and its 200 day moving average is $1.99. Autolus Therapeutics plc has a fifty-two week low of $1.11 and a fifty-two week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $8.98 million during the quarter, compared to the consensus estimate of $1.59 million. Equities analysts forecast that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on AUTL shares. Truist Financial dropped their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 10th. Finally, Wells Fargo & Company lowered their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Autolus Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.